A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer

Keyphrases

• 35 Gy 20%
• Agent Behavior 20%
• Clinical Experience 20%
• Concurrent Radiotherapy 20%
• Cure Rate 20%
• Cytotoxic Effect 20%
• Dose-limiting Toxicity 20%
• Improved Outcomes 20%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 40%
• Lung Cancer 20%
• Mammalian Target of Rapamycin Pathway 40%
• Maximum Tolerated Dose 20%
• MTOR Inhibitor 20%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Partial Response 20%
• Phase I Study 100%
• Pneumonitis 20%
• Pulmonary Hemorrhage 20%
• Radiation Effects 20%
• Radiation Therapy 20%
• Stable Disease 20%
• Sudden Death 20%
• Targeted Agents 20%
• Targeted Therapy 20%
• Temsirolimus 100%
• Thoracic Radiation 100%

Medicine and Dentistry

• Cytotoxicity 20%
• Disease 20%
• Lung Cancer 20%
• Mammalian Target of Rapamycin Inhibitor 20%
• Mechanistic Target of Rapamycin 40%
• Non Small Cell Lung Cancer 100%
• Pneumonia 20%
• Pulmonary Hemorrhage 20%
• Radiation Therapy 40%
• Sudden Death 20%
• Targeted Therapy 20%
• Temsirolimus 100%